Dr Yuewei Xu did his undergrad study in the Department of Biological Sciences at XJTLU (2013-2017) and then completed MRes (Cancer Biology) and PhD study at Imperial College London. During the PhD, his research focused on developing novel combination therapies for PARP inhibitor resistant ovarian cancer. Later, he worked in WuXi Biologics (Shanghai) for 1.5 years and led a team of four scientists. His group has helped multiple clients developing cell lines, producing biopharmaceuticals, and optimizing culture process for large scale production.

Driven by passion for teaching and research, Yuewei came back to academia. He felt studying at XJTLU was a life-changing experience and he hope more students can feel the same.

Here at XJTLU, Yuewei's research uses drug combination screens to identify novel drug combinations for cancer treatment. He is also interested in studying how alternative RNA splicing may affect cellular response to DNA damage and other stresses. 

Over the years of study and reserach, Yuewei has used a range of functional assays that are very useful for cancer research, such as cell growth, apoptosis, cell cycle, DNA damage, RNA splicing, 3D cell invasion assays, and synergy analysis. 

If you are interested in working with Yuewei, please feel free to send an email or visit office SD334G for a chat.

Office hour: Wed 15:00 - 16:00

(Office hours may be adjusted in case of time conflicts. )

• 2024 Poster Award (2nd place), ZOMES meeting, Shenzhen China.
• 2018-2022 Full PhD scholarship by China Scholarship Council & Imperial College London.
• 2017 Top Project Award for BSc thesis, Royal Society of Biology, UK
• 2017 Best Performance in FYP, XJTLU, China
• 2017 Best Overall Academic Performance, XJTLU, China
• 2016 National Scholarship by the Ministry of Education, China
• 2014-2016 XJTLU scholarships (3 times) 

APH430 Quality Assurance for Drugs and Biologics

APH428 Quality Systems and Standards

APH438 Advanced Pharmacotherapy (co-teaching)

RNA splicing in cancer

Drugs (PROTACs or inhibitors) for splicing factors

Novel combination therapies and synthetic lethality